Why the DIM « Thérapie Génique » ?

The Paris Region is a pioneer in the field of gene therapy. In 1999, the first gene therapy protocol to treat children with severe immunodeficiency (X-SCID) was developed by Pr. Alain Fischer, Marina Cavazzana and Salima Hacein-Bey and launched at the Necker – Enfants malades University Hospital.

The Paris Region hosts several key actors involved in gene therapy. The DIM « thérapie génique » aims to federate them and accelerate the development of gene therapy to reinforce, in the light of personalized medicine, it grades among the most promising and innovative therapeutic strategies. This initiative aims to provide treatment for serious or chronic pathologies without treatment till today, or for which the medical care is still largely not satisfying.